Bicara Therapeutics Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Bicara Therapeutics Inc in the second quarter 2026?
Bicara Therapeutics Inc recorded a cumulative net loss of $-185 million during 12 months ending in the second quarter 2026, resulting in a negative return on equity (ROE) of -41.49%.

Within the Major Pharmaceutical Preparations industry 144 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 2552 to 3063.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Equity Change	7.71 %	11.98 %	-18.38 %	-20.95 %	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in Millions	-185	-157	-138	-122	-103
Return On Equity (TTM)	-41.49 %	-35.89 %	-32.49 %	-27.17 %	-21.67 %
BCAX's Total Ranking	# 3063	# 2552	# 2715	# 0	# 2373
Equity (TTM) in Millions	469	514	401	403	435
Seq. Equity Change	-8.79 %	28.02 %	-0.33 %	-7.45 %	-5.18 %
Seq. Net Income Change	-	-	-	-	-

Back to BCAX Management Effectiveness >> BCAX's 5 Years Annual ROE >> Compare BCAX ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 145
Sector	# 372
Overall	# 3063

Return On Equity Statistics
High	Average	Low
-21.67 %	-31.14 %	-41.49 %
(Jun 30 2025)		(Jun 30 2026)

BCAX Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024
Total Equity in Millions	401	492	0	0	0
Y / Y Equity Change	-18.38 %	-	-	-	-
Net Income in Millions	-138	-68	0	0	0
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	-34.36 %	-13.82 %	-	-	-

Back to BCAX Management Effectiveness >> BCAX's 5 Years Annual ROE >> Compare BCAX ROE to its Competitors

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
BCAX's' Return on Equity at Yahoo Finance
BCAX's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for BCAX's Competitors
Subscribers only: Roe for Bicara Therapeutics Inc 's Suppliers
Subscribers only: Return On Equity for BCAX's Customers

Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector

ROE

Date modified: 2026-09-26T07:43:05+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.